M&A Opportunity

Gamma Pharmaceutical
Manufacturer
Vietnam

1
Private & Confidential
 Investment Opportunity – Gamma Pharmaceutical Manufacturing Listed Company
[ HIGHLIGHT] Company Overview Key Product
General introduction Operation • Antibiotics: Cefuroxim, Cefixim, betalactam and non-betalactam
• Respiratory products: Theophylin, Salbutamol, Terpin codein, Acetylcystein
Industry Pharmaceutical Manufacturing Number of manufacturing ~ 200 different kinds of • Digestive & hepatobiliary: Sorbitol, Loperamid
Listed Company products drug • Anti-Histamin & antiallergic: Cetirizin
Location Southern Vietnam • Cardiovascular: Rutin, Captopril
Number of distributed and ~ 1,500 local drugs • Corticosteroid: Dexamethason, Prednisolon
Employees ~ 350 imported drugs ~ 3,000 imported drugs
Established Since 1970s All of the products are patented and GMP – WHO certified, quality assurance is GLP
Factory 2 factories with GMP –
approved and storage has GSP certificate. In which two of the main drugs have received
Main Products Manufacture analgesic, antipyretic, WHO certified production
multiple awards and are specially producing focus with more than 50 million capsule
respiratory and intestinal drugs and chain
capacity per year. Betalactam and non betalactam has modern manufacturing chain.
some drugs of the new generation Furthermore, the target is now investing in Herbal medicine manufacturing factory to
antibiotics. Product quality certificate ISO 9001:2008
take advantage of the local region supplies and rising demands of natural medicine.
Management Team Distribution network Market overview
Board Title Experience • 8 selling centers Pharma market in Vietnam is
BOD Chairman/ President 40 years of experience in pharmacy • 2 drug stores ranked 13th in the world based
manufacturing • 8 drug counters on growth rate, total Vietnam
Vice President Over 30 years experience in the industry • 500 distribution agents pharma market size in 2018 is 5.9
• Drug supplies agreement to most of billion USD and is expected to
Director 25 years in the industry
major hospitals in HCMC reach 16.1 billion USD in 2026.
Director 20 years in the industry Financial Highlight Drug spend per person is
• Net revenue in 2019: 12 million USD estimated to growth at 14% y-o-y
BOM Over 25 years in the industry
VP Operations
• Gross profit: 2.5 million USD and will reach 163 USD in 2025.
VP Finance 40 years in Finance & Accounting
• Profit margin: 20.5% Percentage of spending on drugs
• Y-o-y revenue growth rate 2018- is 33% in total health care
Chief Accounting Over 20 years in the industry spending in Vietnam.
2019: 5%
[FUNDING]
Deal Structure
Majority shareholders want to sell 51% of ownership in the company

2
Private & Confidential
IMM FDI Service – About us

With more than 14 years of experience in investment

advisory, together with a wide range of network of clients
and partnerships in Vietnam and Worldwide, IMM FDI
Services provide end-to-end M&A services for Foreign
Direct Investors to Vietnam.

As the local boutique M&A Advisory Firm, we help FDI

investors to expand their business in Vietnam via M&A
strategy. Our edging advantage is the deep and
comprehensive local understanding of Vietnam’s market
and that knowledge successfully helps us to meet our
client’s short-and long-term strategic and investment
objectives.
Mr Jack Tran Lam Binh
FDI Service Director at IMM Group
Email: jack@immgroup.com
Phone: +84 983 099 423

3
Private & Confidential
IMM FDI services – what we offer

Deal matching
Connect the investors with
highly potential
projects/companies in
Vietnam
M&A Financial valuation
Enterprise licensing
Deal Sourcing
Obtaining potential list of
companies in Vietnam with
tailored-criteria to meet
with investors demands
Deal sourcing Enterprise licensing
including establishing
Deal matching companies service in
Vietnam
.

M&A financial valuation

M&A due diligence
M&A/Project Licensing
M&A Due Diligence

M&A/Project Licensing

4
Private & Confidential
IMM FDI services – Our envisaged process

Step 6
Step 5 Signing contracts
and closing deals
Step 4 Perform valuation
analysis and due
Step 3 Organize meetings diligence;
between investors negotiation
Step 2 and targeted advising
Proceed to sign
NDA with investors companies/project
Step 1 Search for to begin business
potential planning and
companies and negotiations
Develop an
investment match with
strategy to fit with investors
your personal
investment criteria
and philosophy

5
Private & Confidential
Our diversified pipelines

Our clients are located across Vietnam and include businesses, private equities, private individuals and families.

• Hotel, resort, golf club

• Residential, service apartments • Transportation service
Real estate • Industrial park, factories companies
Transportation
• Commercial complex • Automobile: manufacturing,
maintenance and accessories
• Office building

• Kindergarten • Power plant station (hydropower,

Education Energy
• Elementary, secondary, high school solar, wind, thermal energy)

• Hospital • Payment solution

Health services • Pharmacy • Financial services
Financial
• Drugstore chain • Stock securities
• E-commerce
• Food manufacturer (instant
noodles, seafood, livestock, canned
food, etc) • Media company
F&B • Beverage (non-alcohol) • Film production
Multimedia
• F&B chain • Advertisement
• Restaurants • Game developer and distributor

• Terminals, airports, seaports,

highway • Wood manufacturer, interior
Infrastructure • Water disposal and supply Others design, software,
• Road, sewage, electrical grid telecommunication and insurance
network

6
Private & Confidential
Disclaimer

By receiving this document, the recipient acknowledges that (i) the recipient will not copy, reproduce or distribute this
document, whether in full or in part, at any time to third parties without the prior written consent of IMM Group, (ii) the
recipient will keep confidential any information included herein which is not already in the public domain, (iii) the recipient
will use this document for the sole purpose of evaluating its interest in the project, (iv) in the event at any time IMM Group
so request, this document, together with all other material relating to the project which the recipient may have been
received from IMM Group elaborated based on those materials and information, will be immediately returned to IMM
Group or destroyed with written confirmation of such destruction to IMM Group. While the information contained in this
document are provisional and based on sources believed to be reliable, IMM Group have not independently verified the
contents of this document. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance
should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this
document, and none of IMM Group or any of their affiliates, directors, members, officers or employees shall have any
liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its
contents or otherwise arising in connection with this document. In all cases, interested parties should conduct their own
investigation and analysis of the project and the data contained in this document. This document may not be reproduced
or redistributed to any other person or published in whole or in part for any purpose. By receiving this document you agree
to be bound by the all limitations. This document should be used solely to enable the recipient to evaluate its interest in
the project. This Teaser does not constitute an offer or invitation for the sale or purchase of securities or any businesses or
assets described in it, nor does it purport to give legal, tax or financial advice. The recipient acknowledge and represent to
the Company, its affiliates, controlling persons, directors, supervisors, officers, partners, employees, agents,
representatives and advisers of any of the foregoing that the recipient are a professional investor, have the knowledge,
experience and capability to conduct their own assessment of the project and its securities and that the recipient have and
will conduct their own investigation with respect to the project and its securities and have obtained or will obtain their own
independent advice relating to the investment in the securities of the project.

7
Private & Confidential